Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in the treatment of brain metastases (BMs). Additionally, the Phase I for EVT801 is expected to begin enrolment by year-end.
14 Oct 2021
Kazia Therapeutics - Multiple paxalisib data points expected in Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Kazia Therapeutics - Multiple paxalisib data points expected in Q4
- Published:
14 Oct 2021 -
Author:
Maxim Jacobs -
Pages:
7
Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in the treatment of brain metastases (BMs). Additionally, the Phase I for EVT801 is expected to begin enrolment by year-end.